FDA: Risk builds up with Tysabri infusions
FDA sent out a new Tysabri warning Friday, one emphasizing that the risk of a rare brain infection increases as treatment continues. Biogen Idec, which markets the multiple sclerosis drug, said the FDA’s warning–and revision of Tysabri’s labeling–was not new.
